Pharmaceuticals
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
Datavault AI and Wellgistics Health Partner to Integrate Blockchain Technology for Prescription Drug Tracking
Datavault AI and Wellgistics Health are collaborating to integrate blockchain-enabled PharmacyChain smart contract technology into pharmaceutical distribution, aiming to enhance prescription tracking efficiency, transparency, and patient safety while exploring a revenue-sharing model.
Branded Legacy Advances FDA Pathway for Low-Cost Intranasal Naloxone Alternative
Branded Legacy's subsidiary BioLegacy Evaluative Group is preparing FDA submission materials for a proprietary intranasal naloxone spray that aims to replicate Narcan's performance while reducing costs and improving global accessibility to opioid overdose reversal medication.
Patented Laonson Pill Cutter Launches Globally on Kickstarter with Automatic Center-Aligning Technology
The Laonson Pill Cutter introduces patented automatic center-aligning technology that ensures precise medication division, addressing a critical healthcare need for accurate dosing across personal and professional settings.
ABVC BioPharma Recognized as Promising Biotech Investment Amid Strong Financial Performance and Clinical Progress
ABVC BioPharma's recognition as a top biotech investment opportunity highlights the company's significant financial growth and advancing clinical pipeline across central nervous system disorders and oncology treatments.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Nutriband Partners with Brand Institute to Develop Global Brand Identity for Abuse-Deterrent Fentanyl Patch
Nutriband Inc. has partnered with Brand Institute to create the worldwide commercial brand identity for AVERSA FENTANYL, positioning the product to potentially become the world's first abuse-deterrent opioid patch with significant implications for addressing the opioid crisis.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Nutriband Files Provisional Patent to Strengthen AVERSA Abuse-Deterrent Technology Protection
Nutriband Inc. has filed a provisional patent application to expand protection for its AVERSA abuse-deterrent transdermal technology, potentially extending patent coverage by 20 years and strengthening the company's position in addressing prescription drug misuse.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
Nutriband Chairman to Present at Emerging Growth Conference, Highlighting Abuse-Deterrent Technology
Nutriband Inc. Chairman Serguei Melnik will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, showcasing the company's AVERSA abuse-deterrent technology for transdermal pharmaceutical products.
ABVC BioPharma Receives $566,000 in Cumulative Payments Under Vitargus Licensing Agreement
ABVC BioPharma has received cumulative payments of $566,000 from ForSeeCon Eye Corporation under their Vitargus licensing agreement, with the funds supporting GMP facility preparation for the biodegradable vitreous substitute's production.
Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.
Nightmare Bacteria Infections Surge in U.S., Prompting Urgent Response from Biotech Sector
The rapid spread of antibiotic-resistant 'nightmare bacteria' in the United States is driving increased focus on biotech companies developing novel treatments to address this growing public health crisis.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
Soligenix Secures $7.5 Million Financing to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, providing critical funding to advance multiple late-stage rare disease treatments including its cutaneous T-cell lymphoma therapy HyBryte™.
FDA Guidance Accelerates Lantern Pharma's Pediatric Brain Cancer Therapy Development
Lantern Pharma received FDA guidance that will help advance its LP-184/STAR-001 therapy for rare pediatric brain cancers toward clinical trials planned for 2026, representing significant progress in treating conditions with limited options.
Branded Legacy Subsidiary Files Provisional Patent for Innovative Intranasal Drug Delivery Platform
Branded Legacy's subsidiary BioLegacy Evaluative Group has filed a provisional patent for an air-powered intranasal drug delivery device that could revolutionize treatment for opioid overdoses and other conditions requiring precise nasal administration.
Quantum BioPharma Shareholders Approve Corporate Direction at Annual Meeting
Quantum BioPharma Ltd. secured full shareholder support for its strategic direction during its annual general meeting, highlighting investor confidence in the company's neurodegenerative and metabolic disorder treatments.
Annovis Bio Appoints Mark Guerin as CFO to Lead Financial Strategy During Critical Late-Stage Trials
Annovis Bio has appointed experienced financial executive Mark Guerin as Chief Financial Officer to guide the company's financial strategy as its lead drug candidate buntanetap advances through late-stage clinical trials for Alzheimer's and Parkinson's disease.
Nutriband to Present AVERSA Technology Strategy at MicroCap Rodeo Conference
Nutriband Inc.'s upcoming presentation at the MicroCap Rodeo Conference highlights the company's strategic direction for its innovative AVERSA abuse-deterrent technology platform, which addresses critical safety concerns in transdermal pharmaceutical delivery.
Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.
Stonegate Capital Partners Initiates Coverage on Medicus Pharma, Highlighting Strategic Pipeline Expansion
Investment firm Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd., emphasizing the company's strategic acquisitions and partnerships that position it for growth in dermatology and infectious disease treatments.
Soligenix Appoints Former White House Economic Advisor Tomas Philipson to Guide Rare Disease Drug Development
Soligenix's appointment of healthcare policy expert Tomas Philipson signals strategic positioning to navigate regulatory pathways for its lead rare disease treatment HyBryte™, potentially accelerating market access for unmet medical needs.
Soligenix Advances Oral Mucositis Treatment SGX942 with Combined Clinical Data Analysis
Soligenix is leveraging positive phase 2 and 3 clinical data to design a second pivotal trial for SGX942, addressing the critical unmet medical need for oral mucositis treatment in cancer patients.
Oncotelic Therapeutics Advances Late-Stage Oncology Pipeline Under Proven Leadership
Oncotelic Therapeutics is progressing multiple late-stage clinical programs in high-unmet-need oncology indications under CEO Dr. Vuong Trieu, whose track record with blockbuster cancer drugs positions the company for potential therapeutic breakthroughs.
Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has obtained FDA approval for a Type C meeting regarding its AVERSA™ abuse-deterrent fentanyl patch technology, marking a significant regulatory milestone in addressing opioid abuse through transdermal pharmaceutical innovation.